In recent studies on lung cancer immunotherapy, we plan to use Durvalumab (HY-P9919A/HY-P9919, MedChemExpress) to treat A549 cell lines (human non-small cell lung cancer cells).
According to existing knowledge, Durvalumab, as a PD-L1-targeted antibody, exerts immune activation by blocking the binding of PD-L1 to PD-1/CD80 on the surface of T cells.
Currently, there are the following confusions:
Are there any literatures that clearly report the in vitro experiments of Durvalumab in A549 cells (such as cell proliferation inhibition, apoptosis induction, or PD-L1 expression regulation)?
What are the recommended drug concentration ranges (such as μM level) and treatment times (such as 24-72 hours)?
[Troubleshooting Questions are selected from MCE customer consultation emails.]
1. Supplementary notes on Durvalumab treatment of A549 cells:
There is no literature that mentions the effective concentration of Durvalumab (Cat. No.: HY-P9919A/HY-P9919) alone for A549 cell lines.
It is worth noting that the background expression level of PD-L1 in the A549 cell line is low, which may affect the direct effect of Durvalumab (PD-L1 targeting antibody) (PMID: 32855386).
It is recommended to optimize the model system through pretreatment strategies (such as cytokine stimulation) in experimental design.
It is mentioned in the published literature (PMID: 32855386) that Mitomycin C (MMC) can activate the ERK/c-JUN/STAT3 signaling pathway, significantly upregulate PD-L1 expression in A549 and other non-small cell lung cancer (NSCLC) cells (Figure 1b-d), and enhance the synergistic anti-tumor effect of PD-L1 antibodies and T cells.
At the same time, positive control cells can be set:
NSCLC cell lines with high PD-L1 expression (such as H460, H1299) can be selected to verify the effect of Durvalumab in the context of high PD-L1 (PMID: 32855386).
Or negative control cells can be set: normal cell lines (such as human umbilical vein endothelial cells HUVEC, normal colon mucosal cells NCM460) can be selected to verify the effect of the drug on non-tumor cells and exclude nonspecific effects (PMID: 32855386).
2. Referenced concentration and time-effects of Durvalumab:
The in vitro experimental concentration of PD-L1 antibody Atezolizumab for A549 treatment is 50 μg/mL, and the treatment time is 24-72 hours (PMID: 32855386.
Durvalumab can refer to a similar range. It is also recommended to set a Durvalumab concentration gradient (such as 10-100 μg/ml) to explore the optimal conditions.
The answer to this question comes from MCE Technical Support.
How to contact us?
- Tel: 609-228-6898
- Fax: 609-228-5909
- E-mail: [email protected]
- Technical Support: [email protected]
- Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA
- Badges
- Science topic
- Similar topics
- Biological Science
- Bioecology
- Systems Ecology
- Landscape Ecology
- Connectivity